Catalyst Health Ventures

Lena Health is a developer of a text-based virtual assistant platform designed to assist patients, particularly those with chronic conditions. The platform utilizes conversational AI technology, supplemented by human support, to streamline care coordination and navigation tasks. By offering a SMS-text live chat option, Lena Health allows clinics to reduce long call queues, enabling patients to schedule appointments more conveniently. Additionally, the platform serves value-based care organizations and payers, helping them enhance medication adherence and improve overall health outcomes for their members. Through this innovative solution, Lena Health aims to facilitate a more efficient management of health tasks and improve patient engagement in their care.

Esperto Medical is a medical device company based in Irvine, California, focused on developing advanced wearable diagnostics for both hospital and remote patient monitoring. The company utilizes innovative resonance sonomanometry technology, which employs acoustic stimulation to provide continuous and noninvasive blood pressure measurements without the need for calibration. By enabling round-the-clock monitoring of vital signs, Esperto Medical’s devices aim to enhance accessibility to medical care through automation, allowing patients to effectively manage their health from home or within clinical settings.

Venova Medical is a company focused on developing innovative vascular access systems for patients undergoing renal replacement therapy, particularly those requiring hemodialysis. Founded in 2018 and headquartered in Los Gatos, California, Venova Medical aims to improve the quality of vascular access by addressing both patient-level and systemic barriers associated with access creation. The company's solutions are designed to facilitate quickly functioning access with reduced need for medical interventions, ultimately enhancing patient outcomes and lowering costs associated with hemodialysis. Through its advancements, Venova Medical seeks to simplify the process of obtaining vascular access for patients in need of critical renal therapies.

Brixton Biosciences is a clinical-stage life sciences company focused on developing innovative therapies for pain management. The company addresses significant unmet needs in both chronic and acute pain treatment, moving beyond traditional systemic approaches. Its flagship product, Neural Ice™, is a drug-free injectable therapy designed to provide safe and effective pain relief through reversible inhibition of nerve activity. This novel solution offers patients a long-lasting relief period, with effectiveness extending from thirty to sixty days following a single injection. By prioritizing non-addictive and locally targeted therapies, Brixton Biosciences aims to transform pain management practices and improve the quality of life for patients suffering from various forms of pain.

AtaCor Medical, Inc. is a medical device company based in San Clemente, California, specializing in innovative solutions for cardiac pacing and rhythm management. Founded in 2014, the company has developed the AtaCor EV Temporary Pacing System, which allows for temporary pacing through a parasternal approach. This system advances a custom pacing lead into the extracardiac tissue between the ribs and pericardium, effectively restoring cardiac rhythm without the need for traditional pacing leads or hardware that typically attach directly to the heart. By facilitating quick deployment of temporary or emergency pacing therapy, AtaCor Medical addresses critical needs in cardiac care.

Avive Solutions, Inc., established in 2017, is a medical technology company based in San Francisco, California. It specializes in the development of Automated External Defibrillators (AEDs) and accompanying software solutions. Avive's primary focus is to remove barriers and simplify the response to Sudden Cardiac Arrest (SCA), empowering anyone to effectively intervene in such emergencies. Their next-generation AED is designed to be easily accessible, user-friendly, and well-maintained, with a connected platform that facilitates data transfer to emergency services and medical professionals, enhancing post-rescue care.

Instylla is a medical equipment supplier based in Bedford, Massachusetts, focused on developing next-generation liquid embolics for interventional radiology. The company specializes in products designed for controlled, complete, and persistent embolization, which enhances the capabilities of healthcare professionals in various clinical applications, including peripheral hemostasis and interventional oncology. Instylla’s flagship offering, the Embrace Hydrogel Embolic System, reflects its commitment to improving patient outcomes through innovative embolization solutions.

Rejoni, Inc. is a medical device company based in Bedford, Massachusetts, founded in 2020. It specializes in developing and commercializing innovative solutions aimed at enhancing the outcomes of gynecological surgical procedures. The company focuses on preventing scar formation after intrauterine interventions, addressing both acute and chronic risks associated with such procedures. By utilizing biomaterials, Rejoni creates gynecological products that prioritize women's health, enabling patients to achieve their desired quality of life both now and in the future.

Avive Solutions, Inc., established in 2017, is a medical technology company based in San Francisco, California. It specializes in the development of Automated External Defibrillators (AEDs) and accompanying software solutions. Avive's primary focus is to remove barriers and simplify the response to Sudden Cardiac Arrest (SCA), empowering anyone to effectively intervene in such emergencies. Their next-generation AED is designed to be easily accessible, user-friendly, and well-maintained, with a connected platform that facilitates data transfer to emergency services and medical professionals, enhancing post-rescue care.

Epitel is a digital health company focused on developing a wearable, wireless EEG monitoring platform aimed at enhancing seizure detection. The company's innovative device utilizes a proprietary cloud-based sensor system combined with advanced artificial intelligence technologies to accurately identify abnormal brain activities. By prioritizing accessibility, affordability, and reliability, Epitel enables physicians, caregivers, and patients with neurological disorders to obtain critical brain health insights, ultimately improving their quality of life and care.

PanTher Therapeutics, Inc. is a biotechnology company focused on developing innovative drug-delivery treatments for cancer. Founded in 2014 and based in Cambridge, Massachusetts, the company has created a proprietary platform that enhances therapeutic responses while minimizing side effects. This technology allows for direct and sustained delivery of drugs to tumor sites, thereby improving the efficacy of treatment and reducing the toxicity often associated with traditional intravenous or oral administration methods. PanTher's distinctive targeting capability positions it to address some of the most challenging cancer types, with a lead investigational candidate aimed at treating pancreatic cancer.

Instylla is a medical equipment supplier based in Bedford, Massachusetts, focused on developing next-generation liquid embolics for interventional radiology. The company specializes in products designed for controlled, complete, and persistent embolization, which enhances the capabilities of healthcare professionals in various clinical applications, including peripheral hemostasis and interventional oncology. Instylla’s flagship offering, the Embrace Hydrogel Embolic System, reflects its commitment to improving patient outcomes through innovative embolization solutions.

Conformal Medical, Inc., established in 2016 and based in Nashua, New Hampshire, specializes in developing medical devices aimed at preventing stroke in patients with atrial fibrillation (AFib). The company's primary product is the CLAAS Technology, a solution designed to seal the left atrial appendage (LAA) in AFib patients. This technology forms part of their conformal left atrial appendage closure (LAAC) system.

AtaCor Medical, Inc. is a medical device company based in San Clemente, California, specializing in innovative solutions for cardiac pacing and rhythm management. Founded in 2014, the company has developed the AtaCor EV Temporary Pacing System, which allows for temporary pacing through a parasternal approach. This system advances a custom pacing lead into the extracardiac tissue between the ribs and pericardium, effectively restoring cardiac rhythm without the need for traditional pacing leads or hardware that typically attach directly to the heart. By facilitating quick deployment of temporary or emergency pacing therapy, AtaCor Medical addresses critical needs in cardiac care.

Aria CV, Inc. is a medical device company based in St. Paul, Minnesota, specializing in treatments for pulmonary arterial hypertension (PAH). Founded in 2010 by Drs. John Scandurra and Karl Vollmers, the company has developed an innovative implantable cardiovascular device aimed at reducing the workload on the right side of the heart. This device holds the potential to enhance both the survival and quality of life for patients suffering from pulmonary hypertension. Aria CV has secured an exclusive license for certain patents from the University of Minnesota, reflecting its commitment to advancing medical technology in this critical area of healthcare.

Conformal Medical, Inc., established in 2016 and based in Nashua, New Hampshire, specializes in developing medical devices aimed at preventing stroke in patients with atrial fibrillation (AFib). The company's primary product is the CLAAS Technology, a solution designed to seal the left atrial appendage (LAA) in AFib patients. This technology forms part of their conformal left atrial appendage closure (LAAC) system.

Lantos Technologies, Inc., established in 2009 and headquartered in Derry, New Hampshire, specializes in developing advanced 3D digital ear scanning technology. The company offers the FDA-cleared AURA system, which captures comprehensive data from the outer ear to deep within the ear canal, enabling designers to create personalized in-ear devices with superior comfort and sound quality. This includes custom in-ear headphones, musicians' monitors, hearing aids, and noise protection solutions. Lantos' technology enhances clinical efficiency for audiologists by providing precise measurements, improving patient outcomes, and streamlining the process for faster turnaround times on custom devices.

Saphena Medical is a medical device company based in West Bridgewater, Massachusetts, founded in 2013. The company specializes in the cardiovascular space and has developed Endoscopic Vein Harvesting technologies. Its flagship product, Venapax, is an all-in-one system designed to provide dissection and simultaneous branch ligation, offering a minimal-touch experience with a focus on specimen quality. The device features a soft, elastomeric tip that remains closed during dissection, providing a smooth surface transition for physicians.

Cruzar Medsystems Inc., founded in 2013 and headquartered in Braintree, Massachusetts, operates in the healthcare sector focused on developing innovative medical devices for vascular access. The company's primary product is a specialized intravascular catheter that features a guidewire with a balloon-actuated distal anchoring system and an everting lumen. This technology enables healthcare professionals to effectively navigate obstructive lesions and treat vascular occlusions, enhancing patient care in peripheral interventions.

Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, specializing in women's health diagnostics. Founded in 2008, it focuses on developing innovative diagnostic tests that aid in the early prediction of a woman's individualized risk for complications during pregnancy, including premature birth, preeclampsia, and gestational diabetes. Sera's proprietary proteomics and bioinformatics platform enables the discovery and commercialization of blood-based biomarker tests, which provide critical information to healthcare providers. Notably, the company's PreTRM® Test assesses the risk of spontaneous premature delivery, facilitating timely interventions for at-risk patients. By addressing the healthcare challenges associated with pregnancy complications, Sera aims to enhance maternal and neonatal health while reducing overall healthcare costs.

nVision Medical Corporation is a privately-held medical device company based in Saratoga, California, focused on advancing women's health innovation. Established in 2009, the company specializes in developing devices to assess and treat female infertility resulting from fallopian tube dysfunction. nVision's products are designed not only to detect conditions such as ovarian cancer and tube blockage but also to address the challenges faced in diagnosing and treating issues within the female reproductive tract. By concentrating on these critical areas, nVision aims to improve clinical outcomes and enhance the overall health of women. As of 2018, nVision Medical operates as a subsidiary of Boston Scientific Corporation.

SpaceOAR is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Its hydrogel is clinically proven to minimize side effects and protect the quality of life for prostate cancer patients undergoing radiation therapy that enables healthcare providers to minimize urinary, sexual, and bowel side effects of the patients. It was founded in 2007 and is headquartered in Bedford, Massachusetts.

Maxwell Health is a provider of a SaaS-enabled online benefits service that simplifies employee benefits and human resources for small to mid-sized employers. Established in 2012 and headquartered in Boston, Massachusetts, with an additional office in Cambridge, the company offers a comprehensive platform that includes a marketplace for various insurance products such as medical, dental, vision, life, and disability benefits. The platform also features tools to streamline HR processes, including benefits administration and payroll, along with a mobile application designed to enhance user experience. Maxwell Health aims to modernize how employees access and utilize insurance, financial, and wellness benefits, ultimately helping American families achieve better health and financial well-being. The company operates as a subsidiary of Sun Life Financial United States and collaborates with benefits advisors and insurance companies to deliver its technology.

Aria CV, Inc. is a medical device company based in St. Paul, Minnesota, specializing in treatments for pulmonary arterial hypertension (PAH). Founded in 2010 by Drs. John Scandurra and Karl Vollmers, the company has developed an innovative implantable cardiovascular device aimed at reducing the workload on the right side of the heart. This device holds the potential to enhance both the survival and quality of life for patients suffering from pulmonary hypertension. Aria CV has secured an exclusive license for certain patents from the University of Minnesota, reflecting its commitment to advancing medical technology in this critical area of healthcare.

Saphena Medical is a medical device company based in West Bridgewater, Massachusetts, founded in 2013. The company specializes in the cardiovascular space and has developed Endoscopic Vein Harvesting technologies. Its flagship product, Venapax, is an all-in-one system designed to provide dissection and simultaneous branch ligation, offering a minimal-touch experience with a focus on specimen quality. The device features a soft, elastomeric tip that remains closed during dissection, providing a smooth surface transition for physicians.

Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, specializing in women's health diagnostics. Founded in 2008, it focuses on developing innovative diagnostic tests that aid in the early prediction of a woman's individualized risk for complications during pregnancy, including premature birth, preeclampsia, and gestational diabetes. Sera's proprietary proteomics and bioinformatics platform enables the discovery and commercialization of blood-based biomarker tests, which provide critical information to healthcare providers. Notably, the company's PreTRM® Test assesses the risk of spontaneous premature delivery, facilitating timely interventions for at-risk patients. By addressing the healthcare challenges associated with pregnancy complications, Sera aims to enhance maternal and neonatal health while reducing overall healthcare costs.

Maxwell Health is a provider of a SaaS-enabled online benefits service that simplifies employee benefits and human resources for small to mid-sized employers. Established in 2012 and headquartered in Boston, Massachusetts, with an additional office in Cambridge, the company offers a comprehensive platform that includes a marketplace for various insurance products such as medical, dental, vision, life, and disability benefits. The platform also features tools to streamline HR processes, including benefits administration and payroll, along with a mobile application designed to enhance user experience. Maxwell Health aims to modernize how employees access and utilize insurance, financial, and wellness benefits, ultimately helping American families achieve better health and financial well-being. The company operates as a subsidiary of Sun Life Financial United States and collaborates with benefits advisors and insurance companies to deliver its technology.

SevenOaks Biosystems, LLC focuses on developing autologous tissue generation equipment.

Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, specializing in women's health diagnostics. Founded in 2008, it focuses on developing innovative diagnostic tests that aid in the early prediction of a woman's individualized risk for complications during pregnancy, including premature birth, preeclampsia, and gestational diabetes. Sera's proprietary proteomics and bioinformatics platform enables the discovery and commercialization of blood-based biomarker tests, which provide critical information to healthcare providers. Notably, the company's PreTRM® Test assesses the risk of spontaneous premature delivery, facilitating timely interventions for at-risk patients. By addressing the healthcare challenges associated with pregnancy complications, Sera aims to enhance maternal and neonatal health while reducing overall healthcare costs.

SpaceOAR is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Its hydrogel is clinically proven to minimize side effects and protect the quality of life for prostate cancer patients undergoing radiation therapy that enables healthcare providers to minimize urinary, sexual, and bowel side effects of the patients. It was founded in 2007 and is headquartered in Bedford, Massachusetts.

Maxwell Health is a provider of a SaaS-enabled online benefits service that simplifies employee benefits and human resources for small to mid-sized employers. Established in 2012 and headquartered in Boston, Massachusetts, with an additional office in Cambridge, the company offers a comprehensive platform that includes a marketplace for various insurance products such as medical, dental, vision, life, and disability benefits. The platform also features tools to streamline HR processes, including benefits administration and payroll, along with a mobile application designed to enhance user experience. Maxwell Health aims to modernize how employees access and utilize insurance, financial, and wellness benefits, ultimately helping American families achieve better health and financial well-being. The company operates as a subsidiary of Sun Life Financial United States and collaborates with benefits advisors and insurance companies to deliver its technology.

Cruzar Medsystems Inc., founded in 2013 and headquartered in Braintree, Massachusetts, operates in the healthcare sector focused on developing innovative medical devices for vascular access. The company's primary product is a specialized intravascular catheter that features a guidewire with a balloon-actuated distal anchoring system and an everting lumen. This technology enables healthcare professionals to effectively navigate obstructive lesions and treat vascular occlusions, enhancing patient care in peripheral interventions.

nVision Medical Corporation is a privately-held medical device company based in Saratoga, California, focused on advancing women's health innovation. Established in 2009, the company specializes in developing devices to assess and treat female infertility resulting from fallopian tube dysfunction. nVision's products are designed not only to detect conditions such as ovarian cancer and tube blockage but also to address the challenges faced in diagnosing and treating issues within the female reproductive tract. By concentrating on these critical areas, nVision aims to improve clinical outcomes and enhance the overall health of women. As of 2018, nVision Medical operates as a subsidiary of Boston Scientific Corporation.

Biocius Life Sciences, Inc. is a company specializing in drug discovery research, established in 2009 and located in Woburn, Massachusetts. As a subsidiary of BioTrove, Inc., Biocius develops advanced technologies, including high-throughput mass spectrometry systems, to facilitate the drug discovery process. The company's innovative approach aims to enhance efficiency and accuracy in identifying potential therapeutic compounds, contributing to advancements in pharmaceutical research and development.

nVision Medical Corporation is a privately-held medical device company based in Saratoga, California, focused on advancing women's health innovation. Established in 2009, the company specializes in developing devices to assess and treat female infertility resulting from fallopian tube dysfunction. nVision's products are designed not only to detect conditions such as ovarian cancer and tube blockage but also to address the challenges faced in diagnosing and treating issues within the female reproductive tract. By concentrating on these critical areas, nVision aims to improve clinical outcomes and enhance the overall health of women. As of 2018, nVision Medical operates as a subsidiary of Boston Scientific Corporation.

Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, specializing in women's health diagnostics. Founded in 2008, it focuses on developing innovative diagnostic tests that aid in the early prediction of a woman's individualized risk for complications during pregnancy, including premature birth, preeclampsia, and gestational diabetes. Sera's proprietary proteomics and bioinformatics platform enables the discovery and commercialization of blood-based biomarker tests, which provide critical information to healthcare providers. Notably, the company's PreTRM® Test assesses the risk of spontaneous premature delivery, facilitating timely interventions for at-risk patients. By addressing the healthcare challenges associated with pregnancy complications, Sera aims to enhance maternal and neonatal health while reducing overall healthcare costs.

Lantos Technologies, Inc., established in 2009 and headquartered in Derry, New Hampshire, specializes in developing advanced 3D digital ear scanning technology. The company offers the FDA-cleared AURA system, which captures comprehensive data from the outer ear to deep within the ear canal, enabling designers to create personalized in-ear devices with superior comfort and sound quality. This includes custom in-ear headphones, musicians' monitors, hearing aids, and noise protection solutions. Lantos' technology enhances clinical efficiency for audiologists by providing precise measurements, improving patient outcomes, and streamlining the process for faster turnaround times on custom devices.

Allegro Diagnostics, founded in 2006 by Dr. Jerome Brody and Dr. Avrum Spira, is a molecular diagnostics company based in Maynard, Massachusetts. The firm specializes in the development and commercialization of advanced genomic tests aimed at diagnosing, staging, and guiding treatment for lung cancer and other lung diseases. Utilizing a proprietary molecular testing platform, Allegro analyzes specific changes in gene expression within airway epithelial cells to detect early signs of lung cancer, particularly in current and former smokers. This innovative approach provides healthcare professionals with essential diagnostic information, facilitating quicker diagnosis and more effective treatment options for patients.

Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, specializing in women's health diagnostics. Founded in 2008, it focuses on developing innovative diagnostic tests that aid in the early prediction of a woman's individualized risk for complications during pregnancy, including premature birth, preeclampsia, and gestational diabetes. Sera's proprietary proteomics and bioinformatics platform enables the discovery and commercialization of blood-based biomarker tests, which provide critical information to healthcare providers. Notably, the company's PreTRM® Test assesses the risk of spontaneous premature delivery, facilitating timely interventions for at-risk patients. By addressing the healthcare challenges associated with pregnancy complications, Sera aims to enhance maternal and neonatal health while reducing overall healthcare costs.

SpaceOAR is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Its hydrogel is clinically proven to minimize side effects and protect the quality of life for prostate cancer patients undergoing radiation therapy that enables healthcare providers to minimize urinary, sexual, and bowel side effects of the patients. It was founded in 2007 and is headquartered in Bedford, Massachusetts.

Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, specializing in women's health diagnostics. Founded in 2008, it focuses on developing innovative diagnostic tests that aid in the early prediction of a woman's individualized risk for complications during pregnancy, including premature birth, preeclampsia, and gestational diabetes. Sera's proprietary proteomics and bioinformatics platform enables the discovery and commercialization of blood-based biomarker tests, which provide critical information to healthcare providers. Notably, the company's PreTRM® Test assesses the risk of spontaneous premature delivery, facilitating timely interventions for at-risk patients. By addressing the healthcare challenges associated with pregnancy complications, Sera aims to enhance maternal and neonatal health while reducing overall healthcare costs.

Lantos Technologies, Inc., established in 2009 and headquartered in Derry, New Hampshire, specializes in developing advanced 3D digital ear scanning technology. The company offers the FDA-cleared AURA system, which captures comprehensive data from the outer ear to deep within the ear canal, enabling designers to create personalized in-ear devices with superior comfort and sound quality. This includes custom in-ear headphones, musicians' monitors, hearing aids, and noise protection solutions. Lantos' technology enhances clinical efficiency for audiologists by providing precise measurements, improving patient outcomes, and streamlining the process for faster turnaround times on custom devices.

Vortex Medical is a medical device company focused on the design, development and commercialization.

SpaceOAR is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Its hydrogel is clinically proven to minimize side effects and protect the quality of life for prostate cancer patients undergoing radiation therapy that enables healthcare providers to minimize urinary, sexual, and bowel side effects of the patients. It was founded in 2007 and is headquartered in Bedford, Massachusetts.

Allegro Diagnostics, founded in 2006 by Dr. Jerome Brody and Dr. Avrum Spira, is a molecular diagnostics company based in Maynard, Massachusetts. The firm specializes in the development and commercialization of advanced genomic tests aimed at diagnosing, staging, and guiding treatment for lung cancer and other lung diseases. Utilizing a proprietary molecular testing platform, Allegro analyzes specific changes in gene expression within airway epithelial cells to detect early signs of lung cancer, particularly in current and former smokers. This innovative approach provides healthcare professionals with essential diagnostic information, facilitating quicker diagnosis and more effective treatment options for patients.

Vortex Medical is a medical device company focused on the design, development and commercialization.

BioTrove, Inc. specializes in micro and nano-scale technology platforms designed for life science research and drug discovery. The company offers several key products, including OpenArray, which facilitates relative gene expression analysis and supports genomic research across various fields such as agriculture, disease research, and public health. Additionally, BioTrove provides the RapidFire platform, enabling the screening of difficult drug targets through mass spectrometry-based assay development, along with the RapidFire mass spectrometry hardware system, which serves as a detection technology for drug screening and in vitro ADME applications. Their innovative systems consist of laboratory instruments and consumables that enhance the efficiency of genomic analysis, high-throughput screening, and molecular diagnostics, thereby accelerating research processes and development across multiple scientific domains.

BioTrove, Inc. specializes in micro and nano-scale technology platforms designed for life science research and drug discovery. The company offers several key products, including OpenArray, which facilitates relative gene expression analysis and supports genomic research across various fields such as agriculture, disease research, and public health. Additionally, BioTrove provides the RapidFire platform, enabling the screening of difficult drug targets through mass spectrometry-based assay development, along with the RapidFire mass spectrometry hardware system, which serves as a detection technology for drug screening and in vitro ADME applications. Their innovative systems consist of laboratory instruments and consumables that enhance the efficiency of genomic analysis, high-throughput screening, and molecular diagnostics, thereby accelerating research processes and development across multiple scientific domains.

Hansen Medical, Inc. specializes in the development, manufacture, and sale of medical robotics aimed at enhancing the positioning, manipulation, and control of catheters and catheter-based technologies. The company offers the Sensei systems and Artisan Control Catheters, which are used in electrophysiology procedures to improve catheter navigation and control. Additionally, Hansen Medical provides the CoHesion 3D Visualization Module, a software tool that enhances physicians' ability to visualize catheter placement in three dimensions. Another key product is the Magellan Robotic System, which facilitates remote navigation and vessel cannulation using a telescoping, robotically steerable catheter. The company markets and supports its products through a combination of direct sales, distributors, and sales representatives. Founded in 2002 and headquartered in Mountain View, California, Hansen Medical operates as a subsidiary of Auris Surgical Robotics, Inc. since July 2016.

GI Dynamics, Inc. is a medical device company that specializes in designing, developing, and manufacturing non-surgical therapies for the treatment of type 2 diabetes and obesity. The company’s primary product, EndoBarrier, is aimed at helping patients manage their condition and reduce obesity without the need for surgical intervention. GI Dynamics serves healthcare providers and third-party distributors, selling its products mainly in Europe, the Middle East, the Asia Pacific, and South America. Founded in 2003, the company is headquartered in Lexington, Massachusetts.

BioTrove, Inc. specializes in micro and nano-scale technology platforms designed for life science research and drug discovery. The company offers several key products, including OpenArray, which facilitates relative gene expression analysis and supports genomic research across various fields such as agriculture, disease research, and public health. Additionally, BioTrove provides the RapidFire platform, enabling the screening of difficult drug targets through mass spectrometry-based assay development, along with the RapidFire mass spectrometry hardware system, which serves as a detection technology for drug screening and in vitro ADME applications. Their innovative systems consist of laboratory instruments and consumables that enhance the efficiency of genomic analysis, high-throughput screening, and molecular diagnostics, thereby accelerating research processes and development across multiple scientific domains.

BioTrove, Inc. specializes in micro and nano-scale technology platforms designed for life science research and drug discovery. The company offers several key products, including OpenArray, which facilitates relative gene expression analysis and supports genomic research across various fields such as agriculture, disease research, and public health. Additionally, BioTrove provides the RapidFire platform, enabling the screening of difficult drug targets through mass spectrometry-based assay development, along with the RapidFire mass spectrometry hardware system, which serves as a detection technology for drug screening and in vitro ADME applications. Their innovative systems consist of laboratory instruments and consumables that enhance the efficiency of genomic analysis, high-throughput screening, and molecular diagnostics, thereby accelerating research processes and development across multiple scientific domains.

Novazyme Pharmaceuticals is a biotech startup that conducts research on a new experimental treatment for Pompe disease.

Novazyme Pharmaceuticals is a biotech startup that conducts research on a new experimental treatment for Pompe disease.

EndoVia Medical is a developer of physician-guided robotic systems for minimally invasive surgery. It develops the Laprotek system, a robotic instrument system for minimally invasive surgeries including general surgery, urology, gynecology, and bariatric surgery, and the ViaCath system, a user interface, and instrument control platform, that allows the surgeon to manipulate catheter instruments deep inside the patient.